Medical AI company Mediwhale will release three research abstracts on its AI-powered cardiovascular disease (CVD) prediction software, Reti-CVD, at the American Heart Association’s (AHA) Scientific Sessions 2024, which will be held from Saturday to Monday at the McCormick Place Convention Center in Chicago, Ill.
The study used large-scale retinal image datasets from Korea, the U.K., and Spain, demonstrating Reti-CVD’s efficacy in predicting coronary artery calcium (CAC) scores measured through cardiac CT across diverse populations.
The findings suggest that Reti-CVD could identify patients at high risk of CVD and serve as a valuable diagnostic tool for guiding treatment decisions. According to Mediwhale, the CAC score, which gauges calcium deposits in the coronary arteries, is recognized as one of the most accurate indicators of cardiovascular disease risk.